Lobby organisation
GSK
Company · Health & pharma · HQ: United Kingdom · Transparency Register entry
As of 7 November 2026, GSK appears in 48 declared MEP meetings (28 different MEPs), most often with European People's Party.
In their own words
“GSK is a global biopharmaceutical company with the purpose to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.”
Read the rest of the statementShow less of the statement
“We are a company where outstanding people can thrive. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology. Our scale and strong R&D and manufacturing footprint in the EU give us a unique opportunity to make a positive impact on the lives of people in the region.”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 48 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2020–2026. Bar length is relative to its busiest year (13 in 2025). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 5 Nov 2026 | Aurelijus Veryga | European Biotech Act and Respiratory Health and Immunisation |
| 2 Jul 2026 | Kristian Vigenin | health policy |
| 30 Jun 2026 | Billy Kelleher | Rare Diseases |
| 23 Jun 2026 | Mario Furore | Biotech act |
| 27 May 2026 | Tiemo Wölken | Biotech Act |
| 26 May 2026 | Katri Kulmuni | biotech I |
| 22 May 2026 | Morten Løkkegaard | Introductory meeting |
| 4 May 2026 | Vytenis Povilas Andriukaitis | Biotech Act |
| 7 Apr 2026 | Wouter Beke | EU Biotech Act I |
| 12 Mar 2026 | Stine Bosse | Biotech Act |
| 3 Mar 2026 | Tomislav Sokol | Health policy |
| 7 Nov 2025 | Stine Bosse | Antimicrobial resistance policy |
| 23 Oct 2025 | Liesbet Sommen | Pharmaceutical legislation + Critical Medicines Act |
| 16 Oct 2025 | Billy Kelleher | Pharmaceutical Issues |
| 13 Oct 2025 | Tiemo Wölken | Pharma Regulation - Incentives for Antimicrobials |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.